Gerresheimer Rejects Takeover Approach from Silgan, Ends Discussions

Gerresheimer has rejected a takeover bid from U.S.-based rival Silgan, with sources indicating that discussions between the two companies have now ceased.

The development follows earlier reports that Silgan had submitted a non-binding offer of approximately €41 per share—more than double Gerresheimer’s prevailing share price at the time. Despite the premium valuation, Gerresheimer has opted not to pursue the proposal.

Market reaction was initially negative, with Gerresheimer shares dropping more than 5% before recovering to trade slightly higher later in the session.

According to sources familiar with the matter, Gerresheimer’s decision is driven by its current strategic priorities, including addressing ongoing accounting issues and advancing plans to divest its U.S.-based subsidiary, Centor.

A spokesperson for Gerresheimer declined to comment on the reported bid, citing company policy on market speculation. Silgan did not respond to requests for comment.

The outcome underscores the challenges facing potential consolidation in the medical packaging sector, where strategic alignment and internal restructuring priorities can outweigh attractive acquisition offers.